Afimoxifene
Showing 1 - 8 of 8
Mammographically Dense Breast Trial in United States (Afimoxifene, Laboratory Biomarker Analysis, Placebo)
Active, not recruiting
- Mammographically Dense Breast
- Afimoxifene
- +3 more
-
Tampa, Florida
- +4 more
Dec 27, 2022
Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma Trial in Chicago (drug, procedure, other)
Recruiting
- Cancer Survivor
- +2 more
- Afimoxifene
- +2 more
-
Chicago, IllinoisNorthwestern University
Dec 2, 2020
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive Trial in United States (Afimoxifene, Laboratory Biomarker Analysis,
Recruiting
- Ductal Breast Carcinoma In Situ
- Estrogen Receptor Positive
- Afimoxifene
- +3 more
-
Chicago, Illinois
- +5 more
Dec 17, 2020
Atypical Hyperplasia, Lobular Carcinoma in Situ Trial in Rochester (Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each
Recruiting
- Atypical Hyperplasia
- Lobular Carcinoma in Situ
- Tamoxifen
- +2 more
-
Evanston, Illinois
- +1 more
Jan 20, 2023
Mammographic Breast Density Trial in Germany, Spain, United States (4-OH tamoxifen, Placebo)
Terminated
- Mammographic Breast Density
- 4-OH tamoxifen
- Placebo
-
Mesa, Arizona
- +18 more
Oct 20, 2021
Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer Trial in Chicago (oral , afimoxifene, tamoxifen
Completed
- Ductal Breast Carcinoma in Situ
- Estrogen Receptor-positive Breast Cancer
- oral placebo
- +3 more
-
Chicago, IllinoisNorthwestern University
Jul 18, 2015
Cyclic Breast Pain, Cyclic Mastalgia Trial (Afimoxifene (0.057%) in hydroalcoholic gel)
Completed
- Cyclic Breast Pain, Cyclic Mastalgia
- Afimoxifene (0.057%) in hydroalcoholic gel
- (no location specified)
Jul 11, 2013
Breast Cancer Trial in Chicago (4-hydroxytamoxifen, breast imaging study, radiomammography)
Completed
- Breast Cancer
- 4-hydroxytamoxifen
- +2 more
-
Chicago, IllinoisRobert H. Lurie Comprehensive Cancer Center at Northwestern Univ
May 17, 2012